The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
Open accessAbstract
SUMMARY Alteration of the PTEN/PI3K pathway is associated with late stage and castrate resistant prostate cancer (CRPC). However, how PTEN loss involves in CRPC development is not clear. Here we show that castration-resistant growth is an intrinsic property of Pten-null prostate cancer (CaP) cells, independent of cancer development stage. PTEN loss suppresses androgen-responsive gene expressions by modulating androgen receptor (AR) transcription factor activity. Conditional deletion of Ar in the epithelium promotes the proliferation of Pten-null cancer cells, at least in part, by down-regulating androgen-responsive gene Fkbp5 and preventing PHLPP-mediated AKT inhibition. Our findings identify PI3K and AR pathway crosstalk as a mechanism of CRPC development, with potentially important implications for CaP etiology and therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Prostate cancer in a transgenic mouse.
Greenberg, N. M., DeMayo, F., Finegold, M. J., Medina, D., Tilley, W. D., Aspinall, J. O., Cunha, G. R., Donjacour, A. A., Matusik, R. J., & Rosen, J. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3439 · Cited by 1,294
Gene expression profiling identifies clinically relevant subtypes of prostate cancer
Lapointe, J., Li, C., Higgins, J. P., van de Rijn, M., Bair, E., Montgomery, K., Ferrari, M., Egevad, L., Rayford, W., Bergerheim, U., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0304146101 · Cited by 1,292
Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412401 · Cited by 1,191
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109
Self-citationAntitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M.-E., Efstathiou, E., Rathkopf, D., Shelkey, J., Yu, E. Y., Alumkal, J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60172-9 · Cited by 1,063
Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Gao, T., Furnari, F., & Newton, A. C. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.008 · Cited by 906
Yu, J., Yu, J., Mani, R.-S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.018 · Cited by 850
Self-citationMyc-driven murine prostate cancer shares molecular features with human prostate tumors
Ellwood-Yen, K., Graeber, T. G., Wongvipat, J., Iruela-Arispe, M. L., Zhang, J., Matusik, R., Thomas, G. V., & Sawyers, C. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00197-1 · Cited by 816
Self-citationA Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis
De Gendt, K., Swinnen, J. V., Saunders, P. T. K., Schoonjans, L., Dewerchin, M., Devos, A., Tan, K., Atanassova, N., Claessens, F., Lécureuil, C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308114100 · Cited by 805
FKBP51 Affects Cancer Cell Response to Chemotherapy by Negatively Regulating Akt
Pei, H., Li, L., Fridley, B. L., Jenkins, G. D., Kalari, K. R., Lingle, W., Petersen, G., Lou, Z., & Wang, L. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.07.016 · Cited by 709
Brognard, J., Sierecki, E., Gao, T., & Newton, A. C. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.017 · Cited by 591
Identification of a Cell of Origin for Human Prostate Cancer
Goldstein, A. S., Huang, J., Guo, C., Garraway, I. P., & Witte, O. N. (2010) · Science · doi:10.1126/science.1189992 · Cited by 554
Self-citationMostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
The program of androgen-responsive genes in neoplastic prostate epithelium
Nelson, P. S., Clegg, N., Arnold, H., Ferguson, C., Bonham, M., White, J., Hood, L., & Lin, B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182376299 · Cited by 482
Plaisier, S. B., Taschereau, R., Wong, J. A., & Graeber, T. G. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq636 · Cited by 468
Self-citationKinkade, C. W., Castillo-Martin, M., Puzio-Kuter, A., Yan, J., Foster, T. H., Gao, H., Sun, Y., Ouyang, X., Gerald, W. L., Cordon-Cardo, C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34764 · Cited by 391
Wu, X., Wu, J., Huang, J., Powell, W. C., Zhang, J., Matusik, R. J., Sangiorgi, F. O., Maxson, R. E., Sucov, H. M., & Roy-Burman, P. (2001) · Mechanisms of Development · doi:10.1016/s0925-4773(00)00551-7 · Cited by 390
Self-citationTargeting the androgen receptor pathway in prostate cancer
Chen, Y., Sawyers, C. L., & Scher, H. I. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.005 · Cited by 389
Development of a novel mouse glioma model using lentiviral vectors
Marumoto, T., Tashiro, A., Friedmann-Morvinski, D., Scadeng, M., Soda, Y., Gage, F. H., & Verma, I. M. (2009) · Nature Medicine · doi:10.1038/nm.1863 · Cited by 353
Tanaka, H., Kono, E., Tran, C. P., Miyazaki, H., Yamashiro, J., Shimomura, T., Fazli, L., Wada, R., Huang, J., Vessella, R. L., et al. (2010) · Nature Medicine · doi:10.1038/nm.2236 · Cited by 339
Self-citationCunha, G. R. (1994) · Cancer · doi:10.1002/1097-0142(19940801)74:3+<1030::aid-cncr2820741510>3.0.co;2-q · Cited by 328
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone
Roudier, M. P., True, L. D., Higano, C. S., Vesselle, H., Ellis, W., Lange, P., & Vessella, R. L. (2003) · Human Pathology · doi:10.1016/s0046-8177(03)00190-4 · Cited by 311
Role of stroma in carcinogenesis of the prostate
Cunha, G. R., Hayward, S. W., & Wang, Y. Z. (2002) · Differentiation · doi:10.1046/j.1432-0436.2002.700902.x · Cited by 298
Small cell carcinoma of the prostate part I a clinicopathologic study of 20 cases
Tětu, B., Ro, J. Y., Ayala, A. G., Johnson, D. E., Logothetis, C. J., & Ordonez, N. G. (1987) · Cancer · doi:10.1002/1097-0142(19870515)59:10<1803::aid-cncr2820591019>3.0.co;2-x · Cited by 278
Basal epithelial stem cells are efficient targets for prostate cancer initiation
Lawson, D. A., Zong, Y., Memarzadeh, S., Xin, L., Huang, J., & Witte, O. N. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913873107 · Cited by 275
Self-citationAndrogen receptor is a tumor suppressor and proliferator in prostate cancer
Niu, Y., Altuwaijri, S., Lai, K.-P., Wu, C.-T., Ricke, W. A., Messing, E. M., Yao, J., Yeh, S., & Chang, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804700105 · Cited by 256
Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
Attard, G., Cooper, C. S., & de Bono, J. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.11.006 · Cited by 242
Stiles, B., Groszer, M., Wang, S., Jiao, J., & Wu, H. (2004) · Developmental Biology · doi:10.1016/j.ydbio.2004.06.008 · Cited by 230
Self-citationCunha, G. R., & Chung, L. W. K. (1981) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(81)90338-1 · Cited by 229
Wu, C.-T., Altuwaijri, S., Ricke, W. A., Huang, S.-P., Yeh, S., Zhang, C., Niu, Y., Tsai, M.-Y., & Chang, C. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704940104 · Cited by 211
Sato, N., Sadar, M. D., Bruchovsky, N., Saatcioglu, F., Rennie, P. S., Sato, S., Lange, P. H., & Gleave, M. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.28.17485 · Cited by 202
Lei, Q., Jiao, J., Xin, L., Chang, C.-J., Wang, S., Gao, J., Gleave, M. E., Witte, O. N., Liu, X., & Wu, H. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.031 · Cited by 198
Self-citationLin, H.-K., Hu, Y.-C., Yang, L., Altuwaijri, S., Chen, Y.-T., Kang, H.-Y., & Chang, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300676200 · Cited by 186
Mulholland, D. J., Xin, L., Morim, A., Lawson, D., Witte, O., & Wu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4673 · Cited by 179
Self-citationDirect, Androgen Receptor-Mediated Regulation of the FKBP5 Gene via a Distal Enhancer Element
Magee, J. A., Chang, L.-W., Stormo, G. D., & Milbrandt, J. (2006) · Endocrinology · doi:10.1210/en.2005-1001 · Cited by 174
Jiao, J., Wang, S., Qiao, R., Vivanco, I., Watson, P. A., Sawyers, C. L., & Wu, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4202 · Cited by 172
Self-citationAttard, G., Reid, A. H. M., Olmos, D., & de Bono, J. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4531 · Cited by 168
Impaired prostate tumorigenesis in Egr1-deficient mice
Abdulkadir, S. A., Qu, Z., Garabedian, E., Song, S.-K., Peters, T. J., Svaren, J., Carbone, J. M., Naughton, C. K., Catalona, W. J., Ackerman, J. J. H., et al. (2001) · Nature Medicine · doi:10.1038/83231 · Cited by 162
Targeting the stromal androgen receptor in primary prostate tumors at earlier stages
Niu, Y., Altuwaijri, S., Yeh, S., Lai, K., Yu, S., Chuang, K., Huang, S., Lardy, H. A., & Chang, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804701105 · Cited by 149
PTEN, Stem Cells, and Cancer Stem Cells
Hill, R., & Wu, H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r800071200 · Cited by 145
Self-citationKunderfranco, P., Mello-Grand, M., Cangemi, R., Pellini, S., Mensah, A., Albertini, V., Malek, A., Chiorino, G., Catapano, C. V., & Carbone, G. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010547 · Cited by 143
Immunophilin Chaperones in Steroid Receptor Signalling
Ratajczak, T., Ward, B. K., & Minchin, R. F. (2003) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026033451934 · Cited by 134
Lin, H., Hu, Y., Lee, D., & Chang, C. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0117 · Cited by 134
Is EGR1 a Potential Target for Prostate Cancer Therapy?
Gitenay, D., & Baron, V. T. (2009) · Future Oncology · doi:10.2217/fon.09.67 · Cited by 117
PTEN Regulates Mdm2 Expression through the P1 Promoter
Chang, C.-J., Freeman, D. J., & Wu, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401488200 · Cited by 104
Self-citationAndrogen-Regulated Genes in the Murine Epididymis1
Chauvin, T. R., & Griswold, M. D. (2004) · Biology of Reproduction · doi:10.1095/biolreprod.103.026302 · Cited by 97
The EZH2 polycomb transcriptional repressor—a marker or mover of metastatic prostate cancer?
Sellers, W. R., & Loda, M. F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00187-3 · Cited by 87
Gao, H., Ouyang, X., Banach-Petrosky, W. A., Shen, M. M., & Abate-Shen, C. T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1637 · Cited by 87
Simanainen, U., Allan, C. M., Lim, P., McPherson, S. J., Jimenez, M., Zajac, J. D., Davey, R. A., & Handelsman, D. J. (2007) · Endocrinology · doi:10.1210/en.2006-1223 · Cited by 86
PI3K-AKT-mTOR Pathway is Dominant over Androgen Receptor Signaling in Prostate Cancer Cells
Kaarbø, M., Mikkelsen, Ø., Malerød, L., Qu, S., Lobert, V. H., Akgul, G., Halvorsen, T., Mælandsmo, G. M., & Saatcioglu, F. (2010) · Analytical Cellular Pathology · doi:10.1155/2010/290643 · Cited by 85
Zhang, W., Zhu, J. J., Efferson, C. L., Ware, C., Tammam, J. G., Angagaw, M. H., Laskey, J., Bettano, K. A., Kasibhatla, S., Reilly, J. F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4385 · Cited by 78
Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer
THOMAS, G. V., Horvath, S., Smith, B. L., Crosby, K., Lebel, L. A., Schrage, M. I., Said, J. W., Kernion, J. D., Reiter, R. E., & Sawyers, C. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0130 · Cited by 72
Wang, X.-D., Wang, B.-E., Soriano, R. H., Zha, J., Zhang, Z., Modrusan, Z. D., Cunha, G. R., & Gao, W. (2006) · Differentiation · doi:10.1111/j.1432-0436.2006.00135.x · Cited by 67
Yuan, H., Young, C. Y. F., Tian, Y., Liu, Z., Zhang, M., & Lou, H. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0388-7 · Cited by 59
Yang, S., Eltoum, I. A., & Abdulkadir, S. A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20736 · Cited by 34
Androgen sensitivity of prostate epithelium is enhanced by postnatal androgen receptor inactivation
Simanainen, U., McNamara, K. M., Gao, Y., & Handelsman, D. J. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00017.2009 · Cited by 32
Huang, H. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.12.004 · Cited by 26
Trimming of mammalian transcriptional networks using network component analysis
Tran, L. M., Hyduke, D. R., & Liao, J. C. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-511 · Cited by 15
Self-citationEmerging role of FKBP51 in AKT kinase/protein kinase B signaling
Pei, H., Lou, Z., & Wang, L. (2010) · Cell Cycle · doi:10.4161/cc.9.1.10290 · Cited by 14
Cited by
Yue, S., Li, J., Lee, S.-Y., Lee, H. J., Shao, T., Song, B., Cheng, L., Masterson, T. A., Liu, X., Ratliff, T. L., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.019 · Cited by 929
Karantanos, T., Corn, P. G., & Thompson, T. C. (2013) · Oncogene · doi:10.1038/onc.2013.206 · Cited by 866
Genetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Bluemn, E. G., Coleman, I. M., Lucas, J. M., Coleman, R. T., Hernandez-Lopez, S., Tharakan, R., Bianchi-Frias, D., Dumpit, R. F., Kaipainen, A., Corella, A. N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.003 · Cited by 744
Clinical implications of PTEN loss in prostate cancer
Jamaspishvili, T., Berman, D. M., Ross, A. E., Scher, H. I., De Marzo, A. M., Squire, J. A., & Lotan, T. L. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.9 · Cited by 651
Metadata
- Authors
- Mulholland, D. J., Tran, L. M., Li, Y., Cai, H., Morim, A., Wang, S., Plaisier, S., Garraway, I. P., Huang, J., Graeber, T. G., & Wu, H.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2011-06
- Volume
- 19
- Issue
- 6
- Pages
- 792-804
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2165300664
- Cited by
- 516
- References
- 65
- FWCI
- 41.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.